Brian Posner Joins Dyne Therapeutics Board Amidst Expansion Plans
Brian Posner, founder and president of Point Rider Group (UK) Ltd, has joined the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN). The appointment comes as Dyne transitions to a fully integrated biotechnology company, with plans to commercialize its first product in the mid-2020s.
Posner, who brings 35 years of executive, investment, and board leadership expertise, is honored to join Dyne's Board during this pivotal time. Jason Rhodes, chairman of Dyne's Board, welcomed Posner's insights and leadership. John Cox, president and CEO of Dyne, stated that Posner's appointment strengthens the company's Board.
Dyne is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. The company is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
Prior to his current role, Posner served as president and CEO of ClearBridge Advisors and partner at Warburg Pincus. He currently serves as a director of Arch Capital Group (ACGL) and has previously chaired the AQR Funds and Bioverativ (BIVV).
Brian Posner's appointment to Dyne Therapeutics' Board brings a wealth of experience and leadership to the company. As Dyne continues to advance its programs for neuromuscular diseases, Posner's expertise will be invaluable in guiding the company's growth and success.
Read also:
- Saudi Arabia's TASI Surges Past 11,000, Leading Gulf Equities Rally
- TikTok's deal negotiations continue following a conversation between Xi and Trump
- Trump announces agreement with Chinese authorities on TikTok deal
- Quantum Computing Market in the Automotive Sector Forecast to Expand to $6,462.13 Million by 2034
